AvenCell Europe GmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.avencell.com
Clinical Trials
9
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
- Interventions
- Other: Cyclophosphamide (Non-IMP, Lymphodepletion)Other: Fludarabine (Non-IMP, Lymphodepletion)Drug: Allo-RevCAR01-T
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 80
- Registration Number
- NCT05949125
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇩🇪Klinikum der Universität München, Munich, Bavaria, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
- Conditions
- Prostate Cancer
- Interventions
- Drug: UniCAR02-T-pPSMADrug: UniCAR02-T (IMP)
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 16
- Registration Number
- NCT04633148
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
🇩🇪Universitätsklinikum Dresden, Dresden, Sachsen, Germany
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 90
- Registration Number
- NCT04230265
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇩🇪Klinikum der Universität München, Munich, Bavaria, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
- Conditions
- Renal CancerNon-small Cell Lung CancerProstate CancerTransitional Cell Carcinoma
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 23
- Registration Number
- NCT03927573
- Locations
- 🇩🇪
Klinikum rechts der Isar der TU München, Munich, Bayern, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
🇩🇪Universitätsklinikum Marburg, Marburg, Hessen, Germany
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
- Conditions
- Relapsed AMLRefractory AMLAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- AvenCell Europe GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT03516760
- Locations
- 🇩🇪
Universitätsmedizin Mannheim, Mannheim, Baden-Württemberg, Germany
🇩🇪Klinikum rechts der Isar, München, Bayern, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany